Q-omics provides the consensus-scored H3P16 profile across patient tissues and cancer cell-line models. H3P16 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, H3P16 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, H3P16 RNA expression shows 17,023 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where H3P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H3P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H3P16 survival associations across molecular data types. H3P16 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H3P16 RNA expression–survival associations across cancer types. High H3P16 expression shows unfavorable associations in ACC, KICH and UVM, but favorable associations in CESC, COAD and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for H3P16 RNA expression.
This table summarizes H3P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for H3P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H3P16 shows lower tumor expression in KICH and higher tumor expression in LIHC, BLCA, BRCA, COAD and CHOL. The LIHC box plot shows higher H3P16 RNA expression in tumor versus normal tissue (log2 FC = +0.418, t-test p < 0.001).
This table shows molecular features associated with H3P16 in patient tissues and cancer cell lines. In patient samples, H3P16 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
